US Osteoarthritis Drugs Market Report 2022 to 2030

US Osteoarthritis Drugs Market Analysis

$ 3999

US osteoarthritis drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Increased prevalence of osteoarthritis, improvements in drug development R&D, increased funding from private and public organisations for the development of the healthcare sector and research centres, and increased demand for cell-based research activities are the main factors driving the growth of the osteoarthritis drugs market. Some of the major key players in this market are Pfizer Inc., Abbvie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH, etc.

ID: IN10USPH353 CATEGORY: Pharmaceuticals GEOGRAPHY: US AUTHOR: Dr. Medha Sansanwal

Buy Now

US Osteoarthritis Drugs Market Analysis Summary

US Osteoarthritis Drugs Market is valued at around $3837.2 Mn in 2022 and is projected to reach $6302.9 Mn by 2030, exhibiting a CAGR of 6.4% during the forecast period 2023-2030.

Osteoarthritis is a chronic bone disorder associated with the inflammation of the joint cartilage breakdown of the surrounding bone. It is the most common joint disease primarily affecting the joints of the hands, knees, hips, and spine. The signs and symptoms are stiffness, pain, tenderness, and swelling of the joints. This condition generally leads to swelling, tenderness, persistent pain, stiffness, loss of flexibility, grating sensation, bone spurs, and sleep disturbances. It can be diagnosed using X-ray, arthroscopy, physical examination, joint fluid analysis, blood tests, and magnetic resonance imaging (MRI) scans. Although no drug may delay or stop the progression of osteoarthritis, some can lessen or relieve pain, allowing you to be more comfortable and active. Additionally, additional activity can further lessen pain and improve fitness. The majority of drugs used to treat osteoarthritis pain are taken orally. A few of them include anti-inflammatory and analgesics, duloxetine, acetaminophen, and many more. Increased prevalence of osteoarthritis, improvements in drug development R&D, increased funding from private and public organizations for the development of the healthcare sector and research centers, and increased demand for cell-based research activities are the main factors driving the growth of the osteoarthritis drugs market. The major key players in this market are Pfizer Inc., Abbvie Inc., Novartis AG, Amgen Inc., Boehringer Ingelheim International GmbH, Samsungbioepis Co. Ltd, Merck & Co Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca, Zimmer Biomet, Stryker Corporation.

Market Dynamics

Market Growth Drivers

The rise in the prevalence of osteoarthritis, improvements in drug development R&D, increased funding from private & public organizations for the development of the healthcare sector and research centers, and the rise in demand for cell-based research activities are the main factors driving the growth of the osteoarthritis therapeutics market. Due to the increased susceptibility of the elderly to osteoarthritis, the growing geriatric population also contributes to the growth of the osteoarthritis treatment market. In 2020, the Journal of eClinical Medicine revealed that roughly 22% of people over the age of 40 had been diagnosed with knee osteoarthritis worldwide.

Market Restraints

The high cost of hyaluronic acid products and other treatment techniques for osteoarthritis therapy as well as the adverse effects associated with the existing therapies, however, may restrain the expansion of the osteoarthritis treatment market over the anticipated period.

Competitive Landscape

Key Players

Pfizer Inc.
Abbvie Inc.
Novartis AG
Amgen Inc.
Boehringer Ingelheim International GmbH
Samsungbioepis Co. Ltd.
Merck & Co Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceuticals Industries Ltd.
AstraZeneca
Zimmer Biomet
Stryker Corporation

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

US Osteoarthritis Drugs Market Segmentation

By Anatomy

Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Small Joint Osteoarthritis

By Drug Type

Viscosupplementation Agents
Non-steroidal Anti-inflammatory Drugs
Analgesics
Corticosteroids

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.